Comparative Pharmacology
Head-to-head clinical analysis: PANRETIN versus RENOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANRETIN versus RENOVA.
PANRETIN vs RENOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.
Renova (tretinoin) is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ). It modulates gene expression, increasing collagen synthesis, reducing collagen breakdown via inhibition of matrix metalloproteinases, and promoting epidermal cell turnover and proliferation.
Apply 0.1% gel topically to lesions twice daily.
Apply a thin layer to affected area once daily at bedtime. Use only fingertips to apply (0.1% cream).
None Documented
None Documented
Mean terminal half-life of approximately 5-10 hours; clinical context: supports twice-daily topical application.
Terminal half-life is 2-4 hours in patients with normal renal function; prolonged to 18-24 hours in end-stage renal disease
Primarily hepatic metabolism; less than 1% excreted unchanged in urine.
Renal (approximately 99% as unchanged drug), biliary/fecal (<1%)
Category C
Category C
Topical Retinoid
Topical Retinoid